Top

Virology Journal

Published in:

Open Access 01-12-2007 | Research

Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein

Authors: Jared R Patch, Gary Crameri, Lin-Fa Wang, Bryan T Eaton, Christopher C Broder

Published in: Virology Journal | Issue 1/2007

Abstract

Background

Nipah virus (NiV) is an emerging paramyxovirus distinguished by its ability to cause fatal disease in both animal and human hosts. Together with Hendra virus (HeV), they comprise the genus Henipavirus in the Paramyxoviridae family. NiV and HeV are also restricted to Biosafety Level-4 containment and this has hampered progress towards examining details of their replication and morphogenesis. Here, we have established recombinant expression systems to study NiV particle assembly and budding through the formation of virus-like particles (VLPs).

Results

When expressed by recombinant Modified Vaccinia virus Ankara (rMVA) or plasmid transfection, individual NiV matrix (M), fusion (F) and attachment (G) proteins were all released into culture supernatants in a membrane-associated state as determined by sucrose density gradient flotation and immunoprecipitation. However, co-expression of F and G along with M revealed a shift in their distribution across the gradient, indicating association with M in VLPs. Protein release was also altered depending on the context of viral proteins being expressed, with F, G and nucleocapsid (N) protein reducing M release, and N release dependent on the co-expression of M. Immunoelectron microscopy and density analysis revealed VLPs that were similar to authentic virus. Differences in the budding dynamics of NiV proteins were also noted between rMVA and plasmid based strategies, suggesting that over-expression by poxvirus may not be appropriate for studying the details of recombinant virus particle assembly and release.

Conclusion

Taken together, the results indicate that NiV M, F, and G each possess some ability to bud from expressing cells, and that co-expression of these viral proteins results in a more organized budding process with M playing a central role. These findings will aid our understanding of paramyxovirus particle assembly in general and could help facilitate the development of a novel vaccine approach for henipaviruses.

Available only for authorised users

Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW: Nipah virus: a recently emergent deadly paramyxovirus. Science 2000,288(5470):1432-1435. 10.1126/science.288.5470.1432PubMedCrossRef

Wang LF, Yu M, Hansson E, Pritchard LI, Shiell B, Michalski WP, Eaton BT: The exceptionally large genome of Hendra virus: support for creation of a new genus within the family Paramyxoviridae. J Virol 2000,74(21):9972-9979. 10.1128/JVI.74.21.9972-9979.2000PubMedPubMedCentralCrossRef

Mayo MA: Virus taxonomy - Houston 2002. Arch Virol 2002,147(5):1071-1076. 10.1007/s007050200036PubMedCrossRef

Murray K, Eaton B, Hooper P, Wang L, Williamson M, Young P: Flying Foxes, Horses, and Humans: a Zoonosis Caused be a New Member of the Paramyxoviridae. In Emerging Infections. Edited by: Scheld WM, Armstrong D, Hughes JM. Washington, D.C. , ASM Press; 1998:43-58.CrossRef

Chua KB: Nipah virus outbreak in Malaysia. J Clin Virol 2003,26(3):265-275. 10.1016/S1386-6532(02)00268-8PubMedCrossRef

ICDDRB: Outbreaks of encephalitis due to Nipah/Hendra-like viruses, western Bangladesh. In Health Science Bulletin. Volume 1. ICDDR,B Centre for Health and Population Research; 2003:1-6.

ICDDRB: Nipah encephalitis outbreak over wide area of western Bangladeh, 2004. Health Science Bulletin 2004,2(1):7-11.

ICDDRB: Person-to-person transmission of Nipah virus during outbreak in Faridpur District, 2004. Health Science Bulletin 2004,2(2):5-9.

Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda M, Rupprecht C, Bresee J, Breiman RF: Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004,10(12):2082-2087.PubMedPubMedCentralCrossRef

10.

Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, Bowden N, Rollin PE, Comer JA, Ksiazek TG, Hossain MJ, Gurley ES, Breiman RF, Bellini WJ, Rota PA: Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis 2005,11(10):1594-1597.PubMedPubMedCentralCrossRef

11.

Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, Mishra A: Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis 2006,12(2):235-240.PubMedPubMedCentralCrossRef

12.

Eaton BT, Broder CC, Middleton D, Wang LF: Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006,4(1):23-35. 10.1038/nrmicro1323PubMedCrossRef

13.

Halpin K, Young PL, Field HE, Mackenzie JS: Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus. J Gen Virol 2000,81(Pt 8):1927-1932.PubMedCrossRef

14.

Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, bin Adzhar A, White J, Daniels P, Jamaluddin A, Ksiazek T: Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. Emerg Infect Dis 2001,7(3):439-441.PubMedPubMedCentralCrossRef

15.

Olson JG, Rupprecht C, Rollin PE, An US, Niezgoda M, Clemins T, Walston J, Ksiazek TG: Antibodies to Nipah-like virus in bats (Pteropus lylei), Cambodia. Emerg Infect Dis 2002,8(9):987-988.PubMedPubMedCentralCrossRef

16.

Reynes JM, Counor D, Ong S, Faure C, Seng V, Molia S, Walston J, Georges-Courbot MC, Deubel V, Sarthou JL: Nipah virus in Lyle's flying foxes, Cambodia. Emerg Infect Dis 2005,11(7):1042-1047.PubMedPubMedCentralCrossRef

17.

Wacharapluesadee S, Lumlertdacha B, Boongird K, Wanghongsa S, Chanhome L, Rollin P, Stockton P, Rupprecht CE, Ksiazek TG, Hemachudha T: Bat Nipah virus, Thailand. Emerg Infect Dis 2005,11(12):1949-1951.PubMedPubMedCentralCrossRef

18.

Chua KB, Lek Koh C, Hooi PS, Wee KF, Khong JH, Chua BH, Chan YP, Lim ME, Lam SK: Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect 2002,4(2):145-151. 10.1016/S1286-4579(01)01522-2PubMedCrossRef

19.

Lamb RA, Kolakofsky D: Paramyxoviridae: The viruses and their replication. In Fields Virology. 4th edition. Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. Philadelphia, PA , Lippincott Williams & Wilkins; 2001:1305-1340.

20.

Shaw ML, Garcia-Sastre A, Palese P, Basler CF: Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol 2004,78(11):5633-5641. 10.1128/JVI.78.11.5633-5641.2004PubMedPubMedCentralCrossRef

21.

Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF: Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 2003,77(2):1501-1511. 10.1128/JVI.77.2.1501-1511.2003PubMedPubMedCentralCrossRef

22.

Rodriguez JJ, Cruz CD, Horvath CM: Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. J Virol 2004,78(10):5358-5367. 10.1128/JVI.78.10.5358-5367.2004PubMedPubMedCentralCrossRef

23.

Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF: Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol 2005,79(10):6078-6088. 10.1128/JVI.79.10.6078-6088.2005PubMedPubMedCentralCrossRef

24.

Bossart KN, Wang LF, Eaton BT, Broder CC: Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. Virology 2001,290(1):121-135. 10.1006/viro.2001.1158PubMedCrossRef

25.

Bossart KN, Wang LF, Flora MN, Chua KB, Lam SK, Eaton BT, Broder CC: Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol 2002,76(22):11186-11198. 10.1128/JVI.76.22.11186-11198.2002PubMedPubMedCentralCrossRef

26.

Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, Bishop KA, Choudhry V, Dimitrov DS, Wang LF, Eaton BT, Broder CC: Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A 2005,102(30):10652-10657. 10.1073/pnas.0504887102PubMedPubMedCentralCrossRef

27.

Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, Tajyar S, Lee B: EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 2005,436(7049):401-405.PubMed

28.

Diederich S, Moll M, Klenk HD, Maisner A: The nipah virus fusion protein is cleaved within the endosomal compartment. J Biol Chem 2005,280(33):29899-29903. 10.1074/jbc.M504598200PubMedCrossRef

29.

Pager CT, Dutch RE: Cathepsin L is involved in proteolytic processing of the hendra virus fusion protein. J Virol 2005,79(20):12714-12720. 10.1128/JVI.79.20.12714-12720.2005PubMedPubMedCentralCrossRef

30.

Pager CT, Craft WW Jr., Patch J, Dutch RE: A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. Virology 2006,346(2):251-257. 10.1016/j.virol.2006.01.007PubMedCrossRef

31.

Schmitt AP, Lamb RA: Escaping from the cell: assembly and budding of negative-strand RNA viruses. Curr Top Microbiol Immunol 2004, 283: 145-196.PubMed

32.

Cathomen T, Mrkic B, Spehner D, Drillien R, Naef R, Pavlovic J, Aguzzi A, Billeter MA, Cattaneo R: A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. Embo J 1998,17(14):3899-3908. 10.1093/emboj/17.14.3899PubMedPubMedCentralCrossRef

33.

Inoue M, Tokusumi Y, Ban H, Kanaya T, Shirakura M, Tokusumi T, Hirata T, Nagai Y, Iida A, Hasegawa M: A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. J Virol 2003,77(11):6419-6429. 10.1128/JVI.77.11.6419-6429.2003PubMedPubMedCentralCrossRef

34.

Mebatsion T, Weiland F, Conzelmann KK: Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 1999,73(1):242-250.PubMedPubMedCentral

35.

Takimoto T, Murti KG, Bousse T, Scroggs RA, Portner A: Role of matrix and fusion proteins in budding of Sendai virus. J Virol 2001,75(23):11384-11391. 10.1128/JVI.75.23.11384-11391.2001PubMedPubMedCentralCrossRef

36.

Sugahara F, Uchiyama T, Watanabe H, Shimazu Y, Kuwayama M, Fujii Y, Kiyotani K, Adachi A, Kohno N, Yoshida T, Sakaguchi T: Paramyxovirus Sendai virus-like particle formation by expression of multiple viral proteins and acceleration of its release by C protein. Virology 2004,325(1):1-10. 10.1016/j.virol.2004.04.019PubMedCrossRef

37.

Coronel EC, Murti KG, Takimoto T, Portner A: Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus- like particles containing nucleocapsid-like structures. J Virol 1999,73(8):7035-7038.PubMedPubMedCentral

38.

Pantua HD, McGinnes LW, Peeples ME, Morrison TG: Requirements for the Assembly and Release of Newcastle Disease Virus-like particles. J Virol 2006,80(22):11062-11073. 10.1128/JVI.00726-06PubMedPubMedCentralCrossRef

39.

Justice PA, Sun W, Li Y, Ye Z, Grigera PR, Wagner RR: Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol 1995,69(5):3156-3160.PubMedPubMedCentral

40.

Li Y, Luo L, Schubert M, Wagner RR, Kang CY: Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus. J Virol 1993,67(7):4415-4420.PubMedPubMedCentral

41.

Harty RN, Paragas J, Sudol M, Palese P: A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol 1999,73(4):2921-2929.PubMedPubMedCentral

42.

Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP: A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci U S A 2000,97(25):13871-13876. 10.1073/pnas.250277297PubMedPubMedCentralCrossRef

43.

Timmins J, Scianimanico S, Schoehn G, Weissenhorn W: Vesicular release of ebola virus matrix protein VP40. Virology 2001,283(1):1-6. 10.1006/viro.2001.0860PubMedCrossRef

44.

Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, Hevey M, Schmaljohn C, Schmaljohn A, Aman MJ: Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002,195(5):593-602. 10.1084/jem.20011500PubMedPubMedCentralCrossRef

45.

Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y: Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002,76(10):4855-4865. 10.1128/JVI.76.10.4855-4865.2002PubMedPubMedCentralCrossRef

46.

Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y: Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001,75(11):5205-5214. 10.1128/JVI.75.11.5205-5214.2001PubMedPubMedCentralCrossRef

47.

Rolls MM, Webster P, Balba NH, Rose JK: Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 1994,79(3):497-506. 10.1016/0092-8674(94)90258-5PubMedCrossRef

48.

Mebatsion T, Konig M, Conzelmann KK: Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 1996,84(6):941-951. 10.1016/S0092-8674(00)81072-7PubMedCrossRef

49.

Volchkov VE, Volchkova VA, Slenczka W, Klenk HD, Feldmann H: Release of viral glycoproteins during Ebola virus infection. Virology 1998,245(1):110-119. 10.1006/viro.1998.9143PubMedCrossRef

50.

Schmitt AP, Leser GP, Waning DL, Lamb RA: Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J Virol 2002,76(8):3952-3964. 10.1128/JVI.76.8.3952-3964.2002PubMedPubMedCentralCrossRef

51.

Conzelmann KK: Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 2004, 283: 1-41.PubMed

52.

Sutter G, Moss B: Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992,89(22):10847-10851. 10.1073/pnas.89.22.10847PubMedPubMedCentralCrossRef

53.

Staib C, Drexler I, Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol 2004, 269: 77-100.PubMed

54.

Carroll MW, Moss B: E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 1995,19(3):352-4, 356.PubMed

55.

Shiell BJ, Gardner DR, Crameri G, Eaton BT, Michalski WP: Sites of phosphorylation of P and V proteins from Hendra and Nipah viruses: newly emerged members of Paramyxoviridae. Virus Res 2003,92(1):55-65. 10.1016/S0168-1702(02)00313-1PubMedCrossRef

56.

Wang LF, Michalski WP, Yu M, Pritchard LI, Crameri G, Shiell B, Eaton BT: A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals. J Virol 1998,72(2):1482-1490.PubMedPubMedCentral

57.

Moss B: Poxviridae: The viruses and their replication. In Fields Virology. 4th edition. Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. Philadelphia, PA , Lippincott Williams & Wilkins; 2001:2849-2883.

58.

Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, Bellini WJ, Rota PA: Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 2000,271(2):334-349. 10.1006/viro.2000.0340PubMedCrossRef

59.

Yao Q, Hu X, Compans RW: Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces. J Virol 1997,71(1):650-656.PubMedPubMedCentral

60.

Malvoisin E, Wild TF: Measles virus glycoproteins: studies on the structure and interaction of the haemagglutinin and fusion proteins. J Gen Virol 1993,74(Pt 11):2365-2372.PubMedCrossRef

61.

Stone-Hulslander J, Morrison TG: Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J Virol 1997,71(9):6287-6295.PubMedPubMedCentral

62.

Homann HE, Hofschneider PH, Neubert WJ: Sendai virus gene expression in lytically and persistently infected cells. Virology 1990,177(1):131-140. 10.1016/0042-6822(90)90467-6PubMedCrossRef

63.

Wright PJ, Crameri G, Eaton BT: RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch Virol 2005,150(3):521-532. 10.1007/s00705-004-0417-5PubMedCrossRef

64.

Goldsmith CS, Whistler T, Rollin PE, Ksiazek TG, Rota PA, Bellini WJ, Daszak P, Wong KT, Shieh WJ, Zaki SR: Elucidation of Nipah virus morphogenesis and replication using ultrastructural and molecular approaches. Virus Res 2003,92(1):89-98. 10.1016/S0168-1702(02)00323-4PubMedCrossRef

65.

Hyatt AD, Zaki SR, Goldsmith CS, Wise TG, Hengstberger SG: Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect 2001,3(4):297-306. 10.1016/S1286-4579(01)01383-1PubMedCrossRef

66.

Ciancanelli MJ, Basler CF: Mutation of YMYL in the Nipah virus Matrix Protein Abrogates Budding and Alters Subcellular Localization. J Virol 2006,80(24):12070-12078. 10.1128/JVI.01743-06PubMedPubMedCentralCrossRef

67.

Coronel EC, Takimoto T, Murti KG, Varich N, Portner A: Nucleocapsid incorporation into parainfluenza virus is regulated by specific interaction with matrix protein. J Virol 2001,75(3):1117-1123. 10.1128/JVI.75.3.1117-1123.2001PubMedPubMedCentralCrossRef

68.

Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, Eaton BT: Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001,3(4):279-287. 10.1016/S1286-4579(01)01381-8PubMedCrossRef

69.

Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, Negrete OA, Bertolotti-Ciarlet A, Choi DY, McHardy I, Fulcher JA, Su SV, Wolf MC, Kohatsu L, Baum LG, Lee B: N-Glycans on Nipah Virus Fusion Protein Protect against Neutralization but Reduce Membrane Fusion and Viral Entry. J Virol 2006,80(10):4878-4889. 10.1128/JVI.80.10.4878-4889.2006PubMedPubMedCentralCrossRef

70.

Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S: Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005,23(23):3033-3042. 10.1016/j.vaccine.2004.11.070PubMedCrossRef

71.

Sakaguchi T, Kato A, Sugahara F, Shimazu Y, Inoue M, Kiyotani K, Nagai Y, Yoshida T: AIP1/Alix is a binding partner of Sendai virus C protein and facilitates virus budding. J Virol 2005,79(14):8933-8941. 10.1128/JVI.79.14.8933-8941.2005PubMedPubMedCentralCrossRef

72.

Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991,108(2):193-199. 10.1016/0378-1119(91)90434-DPubMedCrossRef

73.

Kobasa D, Rodgers ME, Wells K, Kawaoka Y: Neuraminidase hemadsorption activity, conserved in avian influenza A viruses, does not influence viral replication in ducks. J Virol 1997,71(9):6706-6713.PubMedPubMedCentral

74.

Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D, McEachern J, Pritchard LI, Eaton BT, Wang LF, Bossart KN, Broder CC: A feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006,80(24):12293-12302. 10.1128/JVI.01619-06PubMedPubMedCentralCrossRef

Title: Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein
Authors: Jared R Patch
Gary Crameri
Lin-Fa Wang
Bryan T Eaton
Christopher C Broder
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-4-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Molecular epidemiology of measles viruses in China, 1995–2003

Comparative genomic analysis of the family Iridoviridae: re-annotating and defining the core set of iridovirus genes

Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients

Development of a real-time RT-PCR and Reverse Line probe Hybridisation assay for the routine detection and genotyping of Noroviruses in Ireland

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model

Dengue virus serotype infection specifies the activation of the unfolded protein response

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials